Adoption of the 2025 ACC/AHA guidelines minimally expanded antihypertensive treatment eligibility, confirmed by robust results across PREVENT model variants.
Adoption of the 2025 ACC/AHA guideline results in a minimal expansion of antihypertensive treatment eligibility, supporting risk-based guideline implementation.
Absolute Event Rate: 0% vs 0%
Adoption of the 2025 American College of Cardiology/American Heart Association guideline results in a minimal expansion of antihypertensive treatment eligibility. Results were robust across PREVENT model variants, supporting risk-based guideline implementation.
Metlock et al. (Wed,) reported a other. Adoption of the 2025 ACC/AHA guidelines minimally expanded antihypertensive treatment eligibility, confirmed by robust results across PREVENT model variants.